Quick Answer
Tyra Biosciences, Inc. reported Diluted EPS of $2.01 per share (loss) for fiscal year 2025.
Tyra Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.01 | -33.1% |
| 2024 | -$1.51 | +6.8% |
| 2023 | -$1.62 | -22.7% |
| 2022 | -$1.32 | +30.9% |
| 2021 | -$1.91 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.50 | -22.0% | -6.4% |
| June 30, 2025 | -$0.47 | -46.9% | +0.0% |
| March 31, 2025 | -$0.47 | -34.3% | -14.6% |
| September 30, 2024 | -$0.41 | +16.3% | -28.1% |
| June 30, 2024 | -$0.32 | -3.2% | +8.6% |
| March 31, 2024 | -$0.35 | -25.0% | +28.6% |
| September 30, 2023 | -$0.49 | -63.3% | -58.1% |
| June 30, 2023 | -$0.31 | +13.9% | -10.7% |
- Tyra Biosciences, Inc. showed a decrease of -33.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Tyra Biosciences, Inc.’s diluted eps has declined by 5.2% (from $1.91 per share (loss) to $2.01 per share (loss)).
- The most recent figure is from Tyra Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: